Appelbaum P C
Pennsylvania State University Collegeof Medicine, Hershey Medical Center, Hershey, PA 17033, USA.
Postgrad Med. 2000 Dec;108(7 Suppl Contemporaty):5-16. doi: 10.3810/pgm.12.2000.suppl10.51.
The targets of antibiotic intervention in respiratory tract infections continue to change. For example, the minimum inhibitory concentrations (MICs) of beta-lactams for Streptococcus pneumoniae have increased up to 100-fold in recent years. Because the mechanism of resistance in this respiratory tract pathogen is an alteration in penicillin-binding proteins, the higher the MIC of penicillin, the higher the MICs of all beta-lactams. Macrolide resistance in S pneumoniae is highly prevalent in many countries and correlates with penicillin resistance. Because the mechanisms of resistance to tetracyclines, chloramphenicol, and macrolides share the same transposon, resistance to multiple antibiotics in S pneumoniae is common. Although the prevalence of resistance to fluoroquinolones in S pneumoniae is low, it may well increase once these agents are widely prescribed for pediatric patients. The prevalence of ss-lactamase-producing strains of Haemophilus influenzae is stable even though it differs among individual countries. However, beta-lactam activity against H influenzae varies considerably worldwide. The efficacy of macrolide activity against H influenzae is questionable, and resistance to the fluoroquinolones is rare. Virtually all strains of Moraxella catarrhalis produce beta-lactamase. Most oral antibiotics, including the macrolides, are more active against M catarrhalis than H influenzae. Clearly, reassessment of current prescribing practices is critical if antibiotic efficacy is to be preserved and the risk for selection of resistance minimized in the new millennium.
呼吸道感染中抗生素干预的目标不断变化。例如,近年来β-内酰胺类药物对肺炎链球菌的最低抑菌浓度(MIC)已增加至100倍。由于这种呼吸道病原体的耐药机制是青霉素结合蛋白的改变,青霉素的MIC越高,所有β-内酰胺类药物的MIC也越高。肺炎链球菌对大环内酯类药物的耐药性在许多国家高度流行,且与青霉素耐药性相关。由于对四环素、氯霉素和大环内酯类药物的耐药机制共享相同的转座子,肺炎链球菌对多种抗生素耐药很常见。虽然肺炎链球菌对氟喹诺酮类药物的耐药率较低,但一旦这些药物广泛用于儿科患者,耐药率很可能会增加。即使各国之间存在差异,产β-内酰胺酶的流感嗜血杆菌菌株的流行率保持稳定。然而,β-内酰胺类药物对流感嗜血杆菌的活性在全球范围内差异很大。大环内酯类药物对流感嗜血杆菌的活性疗效存疑,且对氟喹诺酮类药物的耐药性罕见。几乎所有卡他莫拉菌菌株都产β-内酰胺酶。包括大环内酯类药物在内的大多数口服抗生素对卡他莫拉菌的活性比对流感嗜血杆菌更强。显然,如果要在新千年保持抗生素疗效并将耐药性选择风险降至最低,重新评估当前的处方做法至关重要。